Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
ARDUAN (pipecuronium bromide) is a neuromuscular blocking agent administered via injection, used to facilitate intubation and provide skeletal muscle relaxation during anesthesia. It belongs to the aminosteroid class of neuromuscular blockers and works by competitively blocking acetylcholine at the neuromuscular junction. This injectable agent is a legacy product in the anesthesia market with limited modern clinical expansion.
Product is in late-stage lifecycle with minimal linked job activity, suggesting limited sales force infrastructure and declining team size at sponsoring organization.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on ARDUAN offers limited career upside given zero linked job openings and a declining product portfolio slot at Merck. Roles on this product are typically maintenance-focused rather than growth-oriented, appealing primarily to early-career professionals seeking hands-on anesthesia market experience or those nearing career transition.
Worked on ARDUAN at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.